Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial
A novel injectable drug called CBL-514 is drawing attention for reducing visceral fat and targeting fat cells without Ozempic or surgery.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent health coverage details the emergence of a novel injectable drug designed to reduce visceral fat and target fat cells directly. According to reports from outlets including kkam.com, DongA Science, Medical Xpress, the New York Post, and Medscape, the compound is known as CBL-514. The coverage indicates that the treatment functions by selectively inducing apoptosis of fat cells, allowing patients to lose their gut and achieve a flatter stomach within mere weeks. Unlike traditional methods, the drug presents a distinct mechanism that distinguishes it from existing interventions. Specific emphasis across the reported articles highlights the transition of the new obesity drug into phase 3 trials.
Medscape focuses on the results of the phase 2 trial showing reductions in visceral fat, while DongA Science notes that the drug is advancing to phase 3 with claims of destroying fat cells without rebound effects. The New York Post and kkam.com emphasize the aesthetic and practical outcomes, pointing to rapid stomach flattening and presenting the injection as an alternative to existing weight-loss medications like Ozempic or surgical procedures. Context provided within the headlines points to the ongoing evolution of weight-loss treatments, moving toward targeted cellular mechanisms rather than systemic appetite suppression. The distinction is drawn between prior interventions and this next-generation approach, which specifically isolates and destroys fat tissue. Readers are informed that the drug targets fat cells selectively, though the available coverage does not yet specify complete trial metrics, side effect profiles, or regulatory timelines beyond the stated clinical trial phases.
Future developments to watch, based strictly on the current reporting, center on the progress and outcomes of the newly entered phase 3 trials for CBL-514. Coverage does not yet specify exact dates for the completion of these advanced trials or when the drug might become publicly available. Observers will be tracking further medical publications and updates from the outlets currently covering the drug's advancement through the clinical pipeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 42d ago.
Quick answers
What is the name of the novel injectable drug?
The drug is named CBL-514, according to reporting from DongA Science and other outlets.
What stage of clinical trials has the drug reached?
CBL-514 has entered phase 3 trials, following results from its phase 2 trial.
How does the drug work?
Coverage states that the drug selectively induces apoptosis of fat cells to destroy them and reduce visceral fat.
Coverage (5)
- A new drug allows you to lose your gut without Ozempic or surgery! kkam.com · 45d ago
- Next-generation obesity drug CBL-514 enters phase 3, destroying fat cells without rebound DongA Science · 45d ago
- New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells Medical Xpress · 45d ago
- New weight-loss drug could give you a ‘flatter stomach’ in mere weeks New York Post · 45d ago
- Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial Medscape · 45d ago
Topics
Related trends
Does a heart stent prevent future heart attacks in stable patients? 25-year follow-up offers new insight
A 25-year follow-up of the COURAGE trial found no survival benefit from early stenting in patients with stable coronary artery disease.
Validation of clinical and preclinical obesity across global cohorts
A new international study of 844,108 adults shows that a revised diagnostic framework outperforms BMI in identifying obesity health risks.
Common heart pill under scrutiny for older patients as study weighs risks of stopping
A major clinical trial reveals that stopping statin drugs in older adults leads to higher rates of heart attacks, strokes, and death.
After brain surgery, man sees cat's eyes in human faces
A 28-year-old man in the US sees his cat's eyes on human faces following brain surgery, according to a new study.
New study links COVID to fewer long-term health problems
About half of adults with long COVID saw sustained symptom improvement within three years of infection, according to a three-year NIH-funded study published in Annals of Internal Medicine.
Are you an evening snacker? What you need to know
Media outlets examine the drivers behind evening snacking and strategies to manage late-night cravings.